Be part of the knowledge.™

NeuroFrontiers

Clinical research and advancements furthering clinicians’ ability to diagnose and treat neurological disorders never stop. And neither does NeuroFrontiers, a series dedicated to covering them all. Here neurology specialists will find essential updates on conditions affecting the nervous system, spinal cord, and overall brain health.

So if you want to stay up to date on the latest clinical research and news on neurological disorders, then look no further. Because NeuroFrontiers is where neurology specialists and great minds explore the mind itself.

371

LikeLikedUnlike

Episodes 16-30 of 337

LUMINESCE: Assessing Satralizumab in Generalized Myasthenia Gravis
NeuroFrontiers
LUMINESCE: Assessing Satralizumab in Generalized Myasthenia Gravis
Advancements in gMG Management: Zilucoplan as an Alternative to C5 Inhibitors
NeuroFrontiers
Advancements in gMG Management: Zilucoplan as an Alternative to C5 Inhibitors
Examining Inebilizumab in Generalized Myasthenia Gravis: Insights from MINT
NeuroFrontiers
Examining Inebilizumab in Generalized Myasthenia Gravis: Insights from MINT
- Ryan Quigley
  Peer
Genetic Pathways in MS: The Clinical Impact of a Chromosome 2 Variant
NeuroFrontiers
Genetic Pathways in MS: The Clinical Impact of a Chromosome 2 Variant
- Sergio Baranzini, PhD
  Peer
Understanding Antibody-Mediated Demyelinating Diseases: Key Differences From MS
NeuroFrontiers
Understanding Antibody-Mediated Demyelinating Diseases: Key Differences From MS
- Michael Levy, MD, PhD
  Peer
Navigating MS Diagnosis in Older Adults: Distinguishing Comorbidities and Mimics
NeuroFrontiers
Navigating MS Diagnosis in Older Adults: Distinguishing Comorbidities and Mimics
- Le Hua, MD
  Peer
advertisement
MMN in Practice: A Rare Motor Neuropathy Often Misdiagnosed
Medical Industry Feature
MMN in Practice: A Rare Motor Neuropathy Often Misdiagnosed
- Jennifer Caudle, DO
  Peer
- Katie Beadon, MD, MASc, FRCPC
  Peer
Decoding Disability Worsening in MS: The Case for Combining CSF and Serum Biomarkers
NeuroFrontiers
Decoding Disability Worsening in MS: The Case for Combining CSF and Serum Biomarkers
- Ryan Quigley
  Peer
Timing Matters: Influenza Vaccination Response in MS Patients on Ofatumumab
NeuroFrontiers
Timing Matters: Influenza Vaccination Response in MS Patients on Ofatumumab
Clemastine Fumarate and Progressive MS: A Closer Look at Unexpected Risks and Mechanisms
NeuroFrontiers
Clemastine Fumarate and Progressive MS: A Closer Look at Unexpected Risks and Mechanisms
Advances in Alzheimer’s Diagnosis: From Imaging to Artificial Intelligence
NeuroFrontiers
Advances in Alzheimer’s Diagnosis: From Imaging to Artificial Intelligence
- Marc Haut, PhD
  Peer
Transforming Alzheimer’s Care: Anti-Amyloid Therapies and Emerging Genetic Approaches
NeuroFrontiers
Transforming Alzheimer’s Care: Anti-Amyloid Therapies and Emerging Genetic Approaches
- Marc Haut, PhD
  Peer
advertisement
The Future of MS Management: Novel Agents and Clinical Approaches
NeuroFrontiers
The Future of MS Management: Novel Agents and Clinical Approaches
- Marisa McGinley, DO
  Peer
MS Relapse vs Pseudo-Relapse After Infection: COVID-19 Shows Divergent Risk Pattern
NeuroFrontiers
MS Relapse vs Pseudo-Relapse After Infection: COVID-19 Shows Divergent Risk Pattern
Pregnancy and Infant Outcomes in Multiple Sclerosis: Findings from the MAPLE-MS Pharmacovigilance Program
NeuroFrontiers
Pregnancy and Infant Outcomes in Multiple Sclerosis: Findings from the MAPLE-MS Pharmacovigilance Program

Program Chapters

Segment Chapters

Playlist:

Recommended